Merck erhält erstes US-Patent für optimiertes CRISPR-Genomeditierungsverfahren
Merck, ein führendes Wissenschafts- und Technologieunternehmen und Wegbereiter auf dem Gebiet der Genomeditierung, hat heute einen formalen Erteilungsbeschluss des US-amerikanischen Patentamts (United …
OTS0138
Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine
Not intended for US, Canada and UK-based media
OTE0001
FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma
Not intended for US, Canada and UK-based media
OTE0006
Merck to Expand US Biopharmaceutical R&D Facility to Advance Innovative Clinical Pipeline
Not intended for US, Canada or UK-based media
OTE0003
Merck and GSK Announce Global Alliance to Jointly Develop and Commercialize M7824, a Novel Immunotherapy with Potential in Multiple Difficult-to-Treat Cancers
Not intended for US, Canada or UK-based media
OTE0003
Merck Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
Not intended for UK- or US-based media
OTE0001
Merck and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer
Not intended for US, Canada and UK-based media
OTE0009
Merck Announces EMA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer
The information contained is not intended for distribution in the USA, Canada or the UK
OTE0005
Merck Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon
Not intended for distribution in the USA, Canada or UK
OTE0004
OTS0172
Merck Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer
The information contained is not intended for distribution in the USA, Canada or the UK
OTE0007
Merck in Agreement With Cyclica for AI-augmented Screening Platform to Expand Research Capabilities
Not intended for distribution in the USA, Canada or UK
OTE0003
Merck gewinnt 2018 zwei 'R&D 100 Awards' für Innovation
Merck, ein führendes Wissenschafts- und Technologieunternehmen gab heute bekannt, dass es zwei R&D 100 Awards gewonnen hat.
OTS0165
Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant
Refractory Ovarian Cancer
OTE0003
Merck führt BioContinuum(TM)-Plattform für zukunftsweisende Prozessoptimierungen ein
Merck, das lebendige Wissenschafts- und Technologieunternehmen, hat heute seine neue BioContinuum(TM)-Plattform eingeführt, um die Herstellung von Biotherapeutika durch höhere Effizienz, vereinfachte …
OTS0162
